Video

Institutional Perspectives in Cancer- Lung Precision Medicine: Chaired by Jacob Sands, MD

Institutional Perspectives in Cancer- Lung Precision Medicine: Chaired by Jacob Sands, MD

The live filming of this virtual event in our IPC series is now on-demand.

OncLive is proud to present the State of the Science Summits and a new virtual event, Institutional Perspectives in Cancer (IPC). Each summit and webinar will convene for a short meeting designed to educate healthcare professionals on the clinical benefits associated with new science driving new thinking in cancer management. Attendees will not only improve their knowledge of novel treatment approaches, but also leave the event the with confidence and intent to apply state-of-the-art treatment strategies to care for their patients. Each event is dedicated to the latest research in one of the following therapeutic areas: Breast Cancer, Lung Cancer, GU & Prostate Cancer, Hematology, or Melanoma.

The State of the Science Summits and IPC assemble academic and community-based physicians & healthcare professionals across key disciplines from medical and surgical oncology. Specialist experts serve as faculty for these premier and renowned oncology summits, which focus on the most relevant cancer topics to ultimately improve patient care.

Speakers:

  • Michael Cheng, MD | Dana-Farber Cancer Institute
  • Jacob Sands, MD | Dana-Farber Cancer Institute
  • Julia Rotow, MD | Dana-Farber Cancer Institute
  • Ibiayi Dagogo-Jack, MD | Massachusetts General Hospital

Topics:

  • Biomarker Testing in Lung Cancer
  • Neoadjuvant and Frontline Immunotherapy in NSCLC
  • Targeted Therapy for NSCLC

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Bradley McGregor, MD, director, clinical research, Lank Center for Genitourinary Oncology, Marra Lochiatto Investigator, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Reid Merryman, MD
A panel of 5 experts on CLL
Emre Yekedüz, MD
Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH
A panel of 5 experts on CLL
A panel of 5 experts on CLL
Sara M. Tolaney, MD, MPH, chief, Division of Breast Oncology, associate director, Susan F. Smith Center for Women’s Cancers, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
A panel of 5 experts on ADCs